Abstract
Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Recent Patents on Anti-Cancer Drug Discovery
Title:Targeted Drug Delivery for Breast Cancer Treatment
Volume: 8 Issue: 2
Author(s): Sha Jin and Kaiming Ye
Affiliation:
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Abstract: Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Export Options
About this article
Cite this article as:
Jin Sha and Ye Kaiming, Targeted Drug Delivery for Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020003
DOI https://dx.doi.org/10.2174/1574892811308020003 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Novel Strategies of Regenerative Medicine Using Chemical Compounds
Current Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Challenges in Oral Delivery: Role of P-gp Efflux Pump
Current Drug Therapy Polypurine Reverse Hoogsteen Hairpins as a Gene Silencing Tool for Cancer
Current Medicinal Chemistry Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Phytochemical Analysis with Antioxidant and Cytotoxicity Studies of the Bioactive Principles from Zanthoxylum capense (Small Knobwood)
Anti-Cancer Agents in Medicinal Chemistry Ethical Implications of Pharmacogenetics: Shaping the Future of the Field
Current Pharmacogenomics Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Phytoestrogens: Pharmacological and Therapeutic Perspectives
Current Drug Targets A Systematic Review of Meta-Analyses on Gene Polymorphisms and Gastric Cancer Risk
Current Genomics PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery Highly Efficient, Chemoselective Syntheses of 2-Methoxy-4-substituted Pyrimidines
Letters in Organic Chemistry Editorial [Hot Topic: Evolving Drug Targets in DNA Base Excision Repair for Cancer Therapy (Guest Editor: Srinivasan Madhusudan)]
Current Molecular Pharmacology Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Platelet Toll-Like Receptor Expression: The Link Between “Danger” Ligands and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)